INTERLEUKIN-10 EXPRESSION AND CHEMOKINE REGULATION DURING THE EVOLUTION OF MURINE TYPE-II COLLAGEN-INDUCED ARTHRITIS

被引:256
|
作者
KASAMA, T
STRIETER, RM
LUKACS, NW
LINCOLN, PM
BURDICK, MD
KUNKEL, SL
机构
[1] UNIV MICHIGAN,SCH MED,DEPT PATHOL,ANN ARBOR,MI 48109
[2] UNIV MICHIGAN,SCH MED,DEPT INTERNAL MED,DIV PULM & CRIT CARE MED,ANN ARBOR,MI 48109
来源
JOURNAL OF CLINICAL INVESTIGATION | 1995年 / 95卷 / 06期
关键词
CHEMOTACTIC FACTOR; NEUTROPHILS; MONOCYTES; CHEMOKINES; AUTOIMMUNITY;
D O I
10.1172/JCI117993
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
In the enclosed study we have examined the expression and contribution of specific chemokines, macrophage inflammatory protein 1 alpha (MIP-1 alpha) and macrophage inflammatory protein 2 (MIP-2), and interleukin 10 (IL-10) during the evolution of type II collagen-induced arthritis (CIA). Detectable levels of chemotactic cytokine protein for MIP-1 alpha and MIP-2 were first observed between days 32 and 36, after initial type II collagen challenge, while increases in IL-10 were found between days 36 and 44. CIA mice passively immunized with antibodies directed against either MIP-1 alpha or MIP-2 demonstrated a delay in the onset of arthritis and a reduction of the severity of arthritis. On the contrary, CIA mice receiving neutralizing anti-IL-10 antibodies demonstrated an acceleration of the onset and an increase in the severity of arthritis. Interestingly, anti-IL-10 treatment, increased the expression of MIP-1 alpha and MIP-2, as well as increased myeloperoxidase (MPO) activity and leukocyte infiltration in the inflamed joints. These data suggest that MIP-1 alpha and MIP-2 play a crucial role in the initiation and maintenance, while IL-10 appears to play a regulatory role during the development of experimental arthritis.
引用
收藏
页码:2868 / 2876
页数:9
相关论文
共 50 条
  • [31] Interleukin-22 Reduces the Severity of Collagen-Induced Arthritis in Association With Increased Levels of Interleukin-10
    Sarkar, Sujata
    Zhou, Xiaoqun
    Justa, Shivali
    Bommireddy, Swaroopa Rani
    ARTHRITIS AND RHEUMATISM, 2013, 65 (04): : 960 - 971
  • [32] TOLEROGENIC ACTIVITY OF POLYMERIZED TYPE-II COLLAGEN IN PREVENTING COLLAGEN-INDUCED ARTHRITIS IN RATS
    THOMPSON, HSG
    HENDERSON, B
    SPENCER, JM
    HOBBS, SM
    PEPPARD, JV
    STAINES, NA
    CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 1988, 72 (01): : 20 - 25
  • [33] Interleukin-10 suppresses the development of collagen type II-induced arthritis and ameliorates sustained arthritis in rats
    Persson, S
    Mikulowska, A
    Narula, S
    OGarra, A
    Holmdahl, R
    SCANDINAVIAN JOURNAL OF IMMUNOLOGY, 1996, 44 (06) : 607 - 614
  • [34] SUPPRESSION OF TYPE-II COLLAGEN-INDUCED ARTHRITIS BY THE INTRAVENOUS ADMINISTRATION OF TYPE-II COLLAGEN OR ITS CONSTITUENT PEPTIDE ALPHA-1-(II) CB10
    ENGLERT, ME
    LANDES, MJ
    ORONSKY, AL
    KERWAR, SS
    CELLULAR IMMUNOLOGY, 1984, 87 (02) : 357 - 365
  • [35] THE EFFECT OF AN INTERLEUKIN-1 RECEPTOR ANTAGONIST PROTEIN ON TYPE-II COLLAGEN-INDUCED ARTHRITIS AND ANTIGEN-INDUCED ARTHRITIS IN MICE
    WOOLEY, PH
    WHALEN, JD
    CHAPMAN, DL
    BERGER, AE
    RICHARD, KA
    ASPAR, DG
    STAITE, ND
    ARTHRITIS AND RHEUMATISM, 1993, 36 (09): : 1305 - 1314
  • [36] TYPE-II COLLAGEN-INDUCED AURICULAR CHONDRITIS
    MCCUNE, WJ
    SCHILLER, AL
    DYNESIUSTRENTHAM, RA
    TRENTHAM, DE
    ARTHRITIS AND RHEUMATISM, 1982, 25 (03): : 266 - 273
  • [37] Vascular endothelial growth factor expression and regulation of murine collagen-induced arthritis
    Lu, J
    Kasama, T
    Kobayashi, K
    Yoda, Y
    Shiozawa, F
    Hanyuda, M
    Negishi, M
    Ide, H
    Adachi, M
    JOURNAL OF IMMUNOLOGY, 2000, 164 (11): : 5922 - 5927
  • [38] INTERLEUKIN-1 MEDIATED ACCELERATION OF TYPE-II COLLAGEN-INDUCED ARTHRITIS - EFFECTS OF ANTIINFLAMMATORY OR ANTIARTHRITIC DRUGS
    HOM, JT
    GLISZCZYNSKI, VL
    COLE, HW
    BENDELE, AM
    AGENTS AND ACTIONS, 1991, 33 (3-4): : 300 - 309
  • [39] INTERLEUKIN-1 ENHANCES THE DEVELOPMENT OF TYPE-II COLLAGEN-INDUCED ARTHRITIS ONLY IN SUSCEPTIBLE AND NOT IN RESISTANT MICE
    HOM, JT
    COLE, H
    ESTRIDGE, T
    GLISZCZYNSKI, VL
    CLINICAL IMMUNOLOGY AND IMMUNOPATHOLOGY, 1992, 62 (01): : 56 - 65